ORIC Pharmaceuticals Secures $125M to Break New Ground in Cancer Resistance Therapies

ORIC Pharmaceuticals Inc. is thrilled to announce a significant milestone in our journey to overcome resistance in cancer with a successful funding round of $125,000,000. This achievement marks an exciting new chapter for our clinical stage biopharmaceutical company, which prides itself on its innovative approach to developing precision medicines that target key mechanisms of cancer resistance. With headquarters in South San Francisco and San Diego, California, ORIC has been steadfast in its commitment to transforming the lives of patients by advancing groundbreaking therapies in multiple genetically defined cancer indications. The fresh capital will be strategically deployed to accelerate the development of our robust clinical stage pipeline, including ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, and ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, currently being developed for prostate cancer. Additionally, the funding will propel the advancement of ORIC-533, an orally bioavailable small molecule inhibitor of CD73, which plays a pivotal role in resistance to chemotherapy and immunotherapy treatments in multiple myeloma. Beyond these exciting candidates, the investment will further bolster our research and development efforts as we expand our portfolio of precision medicines designed to address various facets of cancer resistance. This infusion of capital not only validates the promise of our science but also paves the way for faster clinical transitions, ensuring that we continue to push the boundaries of cancer treatment. For more information on our work and future updates, please visit www.oricpharma.com and follow us on X or LinkedIn.